日本語 
Avalere Health has established its operations in Japan which marks its first step to extend its business footprint throughout Asia with a unified service delivery model that integrates advisory medical and marketing functions. Junji Yokokawa will direct the Tokyo office which has been established to assist Japanese biopharmaceutical companies with their product launch and commercial operations.
The bigger play here is integration. Japan’s healthcare market is becoming harder to navigate because regulatory pressure, pricing scrutiny, physician engagement, and patient communication are all colliding at once. Most firms still work with fragmented agency networks where market access, medical affairs, and marketing operate separately. Avalere Health is trying to close that gap by putting all three together from the start.
Also Read: Piramal Pharma and Ajinomoto Boost ADC Manufacturing
The company says its Japan team combines local market understanding with global healthcare experience to help biopharma companies move faster from launch planning to long-term market adoption. The expansion also reflects a wider industry trend where healthcare firms are moving toward more connected commercialization strategies instead of isolated consulting or marketing partnerships.
Tokyo becomes another signal that global healthcare players are betting heavily on Japan’s evolving life sciences market.
English